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Single-wall carbon nanotubes present unique opportunities for drug delivery, but have not
advanced into the clinic. Differential nanotube accretion and clearance from critical organs
have been observed, but the mechanism not fully elucidated. The liver has a complex cellular
composition that regulates a range of metabolic functions and coincidently accumulates most
particulate drugs. Here we provide the unexpected details of hepatic processing of covalently
functionalized nanotubes including receptor-mediated endocytosis, cellular trafficking and
biliary elimination. Ammonium-functionalized fibrillar nanocarbon is found to preferentially
localize in the fenestrated sinusoidal endothelium of the liver but not resident macrophages.
Stabilin receptors mediate the endocytic clearance of nanotubes. Biocompatibility is
evidenced by the absence of cell death and no immune cell infiltration. Towards clinical
application of this platform, nanotubes were evaluated for the first time in non-human
primates. The pharmacologic profile in cynomolgus monkeys is equivalent to what was
reported in mice and suggests that nanotubes should behave similarly in humans.
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S
ingle-wall carbon nanotubes (SWCNT) have attracted
immense interest as a platform for pharmaceutical
interventions due to their unique physicochemical
properties and remarkable fibrillar pharmacology1,2. These high
aspect ratio macromolecules can be readily derivatized via covalent
chemical or non-covalent physical means, which advocates for
their consideration in the development of multi-functional
scaffolds capable of targeting disease for diagnostic imaging or
therapeutic drug delivery1,3,4. Despite the potential to assume a
novel position in medical applications, carbon nanotubes have
not entered the clinic due to a limited understanding of their
fate in vivo as well as a lack of consideration for the role
that functionalization confers to pharmacology3. Sidewall-
functionalized SWCNT, covalently appended with multiple
primary amines5, have been shown to undergo very rapid renal
elimination in animal models via glomerular filtration6–12. Thus,
these water-soluble macromolecules exhibited a pharmacokinetic
profile similar to that of a small molecule one-thousandth their
size because they possess a high aspect ratio6,8,11.
Most particulate drugs are scavenged and processed by the
liver1. Hepatic accumulation and subsequent hepatobiliary
elimination of functionalized nanotubes has been reported in
animal models, however, the fraction of the administered dose that
localized in the liver varied tremendously in correlation with the
methods used to functionalize the nanotube6–24. Furthermore,
the hepatic location of SWCNT has generally been described as
liver accumulation with only limited identification of the cell
populations involved in accretion and no information on the
processes of receptor-mediated endocytosis25,26 or explanation of
hepatobiliary elimination. The liver is an essential organ with a
complex cellular architecture that regulates an extensive range of
metabolic functions. The liver is comprised primarily of
hepatocytes, Kupffer cells, liver sinusoidal endothelium (LSEC),
stellate cells, bile duct epithelium and vascular endothelium.
Mapping the cytotopographic distribution and hepatic processing
of functionalized nanotubes is required for understanding their fate
in vivo. These data will, in turn, inform on the optimal applications
and possible toxicities of these unique materials with wider import
for nanomedicine as a whole.
This paper reports several novel and unexpected details of
hepatic processing of covalently functionalized nanotubes
including receptor-mediated endocytosis, cellular trafficking and
biliary elimination. First, water-soluble ammonium-functionalized
fibrillar nanocarbon is found to preferentially localize in the
fenestrated sinusoidal endothelium of the liver but not hepatocytes
or resident macrophages. Second, both scavenger Stabilin receptors
mediate the endocytic clearance of nanotubes. This particular
receptor specificity for nanocarbon leads us to find that lymph
tissue also accumulates carbon nanotubes. Third, we propose a
mechanism for the hepatobiliary elimination of nanocarbon.
Fourth, biocompatibility is evidenced by the absence of cell death
and no immune cell infiltration. Towards clinical application of
this platform, nanotubes were evaluated for the first time in non-
human primates. The pharmacologic profile in cynomolgus
monkeys is equivalent to what was reported in mice and suggests
that nanotubes should behave similarly in humans.
Results
Nanomaterial synthesis and characterization. An ammonium-
functionalized carbon nanotube (fCNT) was used to probe
hepatic processing (Fig. 1a). This nanomaterial was prepared and
characterized as previously described8. Transmission electron
microscopy analysis of solid fCNT confirmed a mean length of
195±69 nm (Fig. 1b). These fCNT were water soluble (10 g l 1)
and chromatographically characterized (Fig. 1c); in addition, they
were rapidly renally filtered in both murine6,8,11 and primate
models. The Raman radial breathing mode feature (234 cm 1)
yielded a nanotube diameter of 0.96 nm (ref. 6). These
amino-functionalized nanotubes were further appended with
fluorescent moieties and metal ion chelates to report location via
multiple imaging modalities and investigate whole body, organ,
cell and intracellular distribution.
Murine pharmacokinetic profile of fCNT. Intravenously
administered fCNT rapidly cleared the blood and a fraction
accreted in the liver or was eliminated intact via the bile. Dynamic
positron emission tomographic (PET) imaging and tissue
collection were performed to assess the whole body pharmaco-
kinetic profile in a naive animal model. High contrast images of a
representative mouse (Fig. 1d) showed that the activity cleared
the vascular compartment by 1 h and was predominantly accreted
in liver, spleen and kidney (earlier images at 3 and 20min are
shown in Supplementary Fig. 1). The balance of the injected dose
(80–85%) was rapidly eliminated to the urine8 as shown by the
bladder image at 60min (Fig. 1d). Time–activity curves for blood
and liver graphically show rapid clearance from the blood
(Fig. 1e) and swift accumulation of a fraction of the injected dose
(ID) in the liver (Fig. 1e,f). Detailed tissue harvest experiments
(Fig. 1f and Supplementary Fig. 2) measured the %ID that
partitioned into the blood, tissue, and bile as a function of time.
Activity was measured in the liver (1.39±0.39%ID g 1), bile
(0.35±0.15%ID g 1), spleen (0.42±0.11%ID g 1), lymph node
(0.47±0.42%ID g 1) and small intestines (the duodenum,
jejunum, and ileum contained 2.17±2.31%ID g 1) at 1 h.
Radiochromatographic analysis of bile harvested from the gall
bladder indicated intact fCNT (Supplementary Fig. 3).
LSEC accumulation of fCNT. Liver accumulated fCNT was
localized exclusively in the hepatic sinusoids, associated with
small-nucleated cells lining the sinusoids (Fig. 2, Supplementary
Figs 4 and 5). fCNT was imaged using anti-AF488
immunofluorescence (IF) staining that was directed at AF488
moieties covalently appended onto the nanotube sidewall. This
anti-AF488 probe was multiplexed with an array of co-stains
selected to distinguish distinct cell types and organelles.
The absence of fCNT in hepatocytes was corroborated with
N-cadherin staining that delineates the hepatocyte plasma
membrane. Controls included mice that were injected with
AF488-alone (Supplementary Fig. 4) or vehicle (Supplementary
Fig. 5) and both were negative for AF488 signal.
The fenestrated LSE that lines the hepatic sinusoids was the
structure that localized fCNT as confirmed by multiplex IF
detection using CD31, Lyve1 (lymphatic vessel endothelial
hyaluronan receptor), anti-AF488, and DAPI stained liver sections
(Fig. 2c–e, Supplementary Fig. 6). CD31 is a pan-endothelial
marker while Lyve1 is a marker for lymphatic vascular endothelial
cells; LSEC express Lyve1 and are a notable exception. The CD31
and Lyve1 membrane markers entirely circumscribed the anti-
AF488 signal, substantiating fCNT clearance into the LSEC
population (Fig. 2d). Vascular endothelium (VE) within the liver
did not accumulate fCNT (Fig. 2e) and called attention to the
differential capacities of specialized fenestrated LSEC and VE to
accumulate and internalize fCNT. Liver sections stained with
MECA32, another VE cell marker, confirmed this finding. Resident
Kupffer cells (Supplementary Fig. 7) and bile duct epithelium
(Supplementary Fig. 8) did not accumulate fCNT.
Receptor-mediated endocytosis and organelle trafficking.
Stabilin-1 and Stabilin-2 are scavenger receptors expressed by LSEC
and both mediated internalization of fCNT based on our data
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in vivo and in vitro. Competitive inhibition of these two fasciclin-
like hyaluronan receptor homologues with heparin reduced the
accumulation of fCNT in liver, spleen and lymph node. Heparin has
been reported to be a substrate for Stabilin-1 and Stabilin-2
(refs 27–29) and both receptors are expressed on the specialized
sinusoidal endothelium of liver, spleen and lymph29–31. Heparin
competition in vivo resulted in a decrease in liver, spleen and lymph
clearance of fCNT versus heparin null controls (P¼ 0.017, 0.0025
and 0.09, respectively) with concomitantly more fCNT in the blood
compartment of the heparin treated mice (P¼ 0.00091) as shown in
Fig. 3a,b, respectively. LSEC isolated from livers strongly expressed
mRNA for both Stabilins and in contrast to Kupffer cell expression
(Fig. 3c and Supplementary Fig. 9). Isolated cell phenotype was
confirmed by FACS analysis (Supplementary Fig. 10). Receptor
specificity for fCNT was confirmed in vitro using CHO cells stably
transfected with full-length human Stabilin-1 or Stabilin-2
expression constructs. Confocal microscopy showed punctate
cellular structures in which fCNT (AF488-positive) co-stained
with each anti-Stabilin-1 and anti-Stabilin-2 antibody, respectively
(Fig. 3d,e; control images are shown in Supplementary Figs 11 and
12). Bound or internalized fCNT was quantified using FACS that
showed significant clearance (Fig. 3f,g) versus CHO-transfected
with an empty vector (negative control); acLDL binding served as
positive control, (Supplementary Fig. 13a,b). Furthermore, the
binding of fCNT was significantly reduced in these Stabilin-
expressing CHO cells in the presence of a challenge from excess
heparin in vitro (Supplementary Fig. 13c,d). Organelle trafficking of
fCNT in the mouse liver was monitored as a function of time.
Punctate anti-AF488 staining patterns were associated with EEA-1
stained early endosomes at 5min after injection; with both GM130
and Giantin stained Golgi compartments at 5min through 1 day;
and Lamp1 stained lysosomes at 40min and 1 day (Fig. 3h–j and
Supplementary Fig. 14).
Hepatic biocompatibility of fCNT. Biocompatibility of functio-
nalized nanotubes in mice was examined as a function of time
(1, 3, 7 or 30 days post injection) using terminal deoxynucleotidyl
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Figure 1 | Nanomaterial characterization and murine pharmacokinetics. (a) Graphic illustration of the ammonium-functionalized single walled carbon
nanotube (fCNT) appended with a DOTA radio-metal ion chelate. NB, Figures are not drawn to scale. (b) TEM image of purified fCNT (scale bar, 500nm).
(c) Reverse-phase HPLC chromatograph of fCNT monitoring the signature ultraviolet–visible absorbance at 330nm. (d) PET projection image of a
representative mouse at 60min post injection. The notations Ki, Li, and Bl indicate the kidneys, liver and bladder, respectively. The head is positioned at the
top of the image. (e) Time–activity curves generated from region-of-interest analysis (%ID g 1 (mean±s.d.)) of liver accumulation (blue lines) and blood
compartment clearance (red lines) in four mice that were PET imaged. (f) Biodistribution data for select tissue and bile (%ID g 1 (mean±s.e.m.)) 1 h after
administration. (NB, A comprehensive pharmacokinetic data set is shown in the Supplementary Fig. 2.)
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transferase dUTP nick end labelling (TUNEL) and cleaved caspase-
3 (CC3) IF staining of immunocompetent mouse liver versus
untreated controls. Few DNA fragmentation (Fig. 4a) or apoptotic
(Fig. 4b) events were noted in either the fCNT-treated or untreated
control mouse livers. Further, no T cell infiltration was detected by
CD3 staining (Fig. 4c). No morphological differences between
treated and control mouse liver was observed by hematoxylin and
eosin (H&E) staining (Fig. 4d). The normalized number of CD3-
positive T cells remained stable throughout the time course of the
study (P40.01 compared with untreated control for all time points)
and was not different compared to untreated control (Fig. 4e). The
AF488-fCNT signal decreased with time (Fig. 4f). Human
hepatocyte microspheres were exposed to fCNT (15 and 30mg l 1)
for 3 days in vitro and remained viable at concentrations exceeding
those used in vivo. No morphological or apoptotic differences
between treated and control spheres was observed by H&E, TUNEL
or CC3 staining (Fig. 4g–l and Supplementary Fig. 15).
Pharmacokinetics and toxicology of fCNT in non-human primates.
Towards clinical application of this fCNT platform, the fCNT
pharmacokinetic and toxicologic profiles were evaluated in naive
non-human primates using PET-computed tomography (PET/
CT) imaging, blood chemistry, haematological analyses and his-
topathology. The fibrillar nanomaterial exhibited similar blood
clearance kinetics, tissue biodistribution, and renal elimination in
a pair of 5 kg cynomolgus monkeys (Macaca fascicularis) as
compared to mice. A 1mg kg 1 dose of [86Y]fCNT was
administered intravenously and had a blood half-life of 6–7min.
The majority of the dose was rapidly eliminated in the urine with
a fraction accumulated in the liver and kidneys (SUV was 1 and
16, respectively). Figure 5a is a fused PET/CT image of
[86Y]fCNT in a non-human primate showing liver and kidney
distribution. Time–activity curves for blood washout and hepatic
clearance were equivalent to what was observed in mice (Fig. 5b).
The nanotubes were also biocompatible as shown by acute and
chronic liver toxicity evaluations of blood chemistry and
haematological indices. Biomarkers indicative of hepatic
injury (alkaline phosphatase, lactate dehydrogenase, alanine
aminotransferase, aspartate aminotransferase and albumin) and
WBC counts were changed little relative to baseline values
(Fig. 5c–h) and agreed with published ranges for similarly aged
male animals32. Histopathological examination of liver, spleen,
and lymph tissue (and other tissue) at necropsy by a pathologist
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Figure 2 | Murine liver sinusoidal endothelium accumulated fCNT in vivo. (a) fCNTwas identified in the hepatic sinusoids at 1 h using anti-AF488 (green)
to map AF488 that was covalently appended to fCNT; N-cadherin (red) was used to demarcate hepatocyte plasma membrane, and 40 , 6-diamidino-2-
phenylindole (DAPI) (blue) to mark nuclei (scale bar, 25mm). (b) A three-dimensional (3D)-rendered image of a confocal z-stack of the sinusoid at 1 h
demonstrated that the anti-AF488 (green) stain was localized within the sinusoidal spaces and associated with smaller nucleated cells but not with any of
the large nucleated hepatocytes. Tissue was stained with anti-AF488 (green)/DAPI (blue)/N-cadherin (red) (scale bar, 25mm). (c) A 3D-rendered image
of a confocal z-stack of the sinusoid shows LSEC marked with Lyve1 (red), nuclei with DAPI (blue), and fCNTwith anti-AF488 (green) (scale bar, 10mm).
The yellow arrow shows LSEC with Lyve1 marker circumscribed around the fCNT signal (This cell is abstracted from the image and shown in d). (d) A 3D-
rendered image of the LSEC (identified in Fig. 2c with the yellow arrow) revealed that the Lyve1 (red) marker entirely circumscribed the anti-AF488 (green)
signal (scale bar, 4mm). (e) The liver VE did not accumulate fCNT (white solid arrow) while the fenestrated LSEC did accumulate fCNT (yellow asterisks).
The liver vascular endothelium was stained with CD31 (red), LSEC marked with Lyve1 (white) and CD31, fCNT (appended with AF488) were located with
anti-AF488 stain (green) and nuclei with DAPI (blue) (scale bar, 10mm).
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was scored normal. These pharmacokinetic and toxicological
fCNT profiles in primates suggest that the favourable
pharmacological properties of fCNT should translate in humans.
Discussion
Nanoparticles, in general, are severely limited by untoward
hepatic clearance and lack of renal clearance. While the bulk of
fCNT are renally cleared6–11, the next most prominent organ
contributing to their accumulation and elimination is the liver.
Data reported herein show the unexpected result that liver
processed fCNT either by receptor-mediated LSEC scavenging or
hepatobiliary elimination. Hepatic biocompatibity of these
nanomaterials was confirmed in rodents and primates and is
now explained by a combination of specific LSEC scavenging and
intact biliary clearance. Hepatic and renal processing and
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Figure 3 | Stabilin-mediated endocytosis of fCNTand LSEC trafficking. (a) Mice were administered 20mg heparin (blue bars) and 0.01mg fCNTshowed
decreased fCNT accumulation in liver, spleen and lymph nodes versus heparin null controls (red bars) and (b) concomitantly more fCNT remained in the
blood of the heparin treated mice after 1 h. (c) PCR analysis of LSEC (black bars) and Kupffer cells (green bars) isolated from mouse liver showed that the
LSEC strongly expressed mRNA for both Stabilin-1 and Stabilin-2. The phenotype of each cell type was confirmed by FACS analysis (Supplementary Fig. 10).
Immunofluorescent confocal images of CHO cells transfected with full-length human (d) Stabilin-1 (scale bar, 2.80 mm) or (e) Stabilin-2 (scale bar,
4.38mm) expressing cells were stained with anti-Stabilin-1 and anti-Stabilin-2 antibodies (red) and anti-AF488 (green) to mark fCNT appended with
AF488, and DRAQ5 to mark nuclei (blue). Punctate cellular structures with co-localized staining were evident in both cases. FACS analysis quantified
bound and internalized fCNT in the CHO-transfected (f) Stabilin-1 (orange bar) and (g) Stabilin-2 (yellow bar) cells versus CHO transfected with an empty
vector (blue bar, negative control). The bars are mean±SD using data from 6 experiments (**Po0.01). acLDL served as a positive control (Supplementary
Fig. 13). Organelle trafficking of intracellular fCNT (anti-AF488 (green)) was observed within LSEC in mouse tissue in punctate patterns and was shown
through co-staining to be associated with different intracellular organelles as a function of time. 3D-rendered confocal images of the (h) early endosome
(EEA-1, red) at 5min after injection; (i) Golgi compartments (Giantin, red) at 40min; and (j) lysosomes (LAMP1, red) at 1 day. A complete time course of
these representative data is shown in Supplementary Fig. 14. White arrows indicate co-localized AF488 signal with respective organelles. GM130 stained
tissue data correlated with the Giantin stained sections and LAMP2 lysosome marker data (not shown) correlated with LAMP1. The nuclei are stained with
DAPI (blue) and scale bars, 5 mm.
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Figure 4 | Hepatic biocompatibility of fCNT. The biocompatibility of fCNT in immunocompetent mice was examined as a function of time (1, 3, 7 or 30
days post injection) using (a) TUNEL and (b) cleaved caspase-3 (CC3) IF staining (green) of liver tissue versus untreated controls (scale bars, 150 mm for
all panels). Few DNA fragmentation or apoptotic events were noted in the fCNT-treated animals relative to untreated control mouse livers. (c) T cell
infiltration was imaged using CD3 staining (red). fCNT appended with AF488 was stained green with anti-AF488. (d) H&E stained mouse tissues
corresponding to (a–c) above. Scale bars are 200mm for all panels. (e) The normalized number of CD3-positive Tcells remained stable throughout the time
course of the study (P40.01 compared with untreated control for all time points) and was not different compared with untreated control. (f) The green
fCNT signal decreased over 30 days (****Po0.0001; **Po0.01, Student’s t-test compared with the untreated control tissue. Images of human hepatocyte
microspheres exposed to 30mg l 1 fCNT for 1 day in vitro remained viable. No morphological or apoptotic differences were observed by H&E (g,h), TUNEL
(i,j) or cleaved caspase-3 (k,l) staining of untreated control hepatocyte microspheres versus fCNT-treated hepatocyte microspheres, respectively. Scale bar,
50mm in all images. The complete 3 day treatment dataset and positive control tissues are shown in Supplementary Fig. 15.
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clearance of this fibrillar nanomaterial are advantageous
biological properties.
Given the important role of the liver in mammalian physiology
and homoeostasis, the absence of fCNT in parenchyma was an
interesting and potentially significant finding that correlated with
the observed biocompatibility of these covalently functionalized
nanomaterials6–16,33–35. The various nonparenchymal cells that
populate the liver sinusoid are interleaved and difficult to
distinguish morphologically with light microscopic examination.
However, in this study we employed specific multiple IF stains to
identify and differentiate between Kupffer cells, LSEC30,36–40, and
Stellate cells41. Our data demonstrate that soluble, molecular
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and (h) white blood cell (WBC) count agreed with published ranges (dotted lines) for similarly aged male animals32.
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fCNT are scavenged by LSEC via a Stabilin receptor-mediated
process. Our physicochemical characterizations indicated that
fCNT is soluble and well dispersed in physiologic milieu and
behaved like a fibrillar macromolecule rather than particulates
which would be expected to be phagocytosed by Kupffer cells38.
Accordingly, we observed no evidence of Kupffer clearance of
fCNT using discrete cell markers to interrogate and unequivocally
identify each sinusoidal cell phenotype. Furthermore, we
confirmed that Kupffer cells did not express either Stabilin
receptor which explained the lack of fCNT clearance by this
resident macrophage.
The hypothesis that macromolecular fCNT remain soluble
and individualized in vivo was supported by this study and
previous reports6–8,11. In direct contrast, non-covalently modified
SWCNT (for example, dispersed with surfactant or polyethylene
glycol (PEG)) exist only for a brief interval in the blood
before displacement of the solubilizing agent by serum
protein17. This disadvantage of non-covalent dispersal is an
existing methodological problem that makes our covalently
functionalized CNT study relevant and impactful moving
forward. Surfactant- and polyethylene glycol-dispersed
nanocarbon suspensions are inherently unstable and readily
aggregate in vivo, rendering these non-soluble materials
susceptible to macrophage opsonophagocytosis21. In addition,
since surfactant-dispersed nanomaterials were unable to
efficiently clear renally, a greater majority of the injected dose
accumulates in liver presumably in macrophages17–22. The
untoward behaviour of non-covalently modified nanotubes
in vivo is in direct contrast to soluble covalently functionalized
fCNT that are rapidly filtered by the kidneys and exhibit only
minimal accumulation in liver, spleen and lymph6–13.
The vascular endothelial termini in the liver, spleen and marrow
are tortuous sinusoids. The hepatic sinusoids interface between the
blood supply and hepatocytes and mediate scavenging and
transport of blood-borne solutes. LSEC are fenestrated endothe-
lium possessing numerous open fenestrae, without diaphragm or
basement membrane30,36–40. A sieve plate morphology and high
endocytic capacity support the unique role of LSEC in solute
trafficking and active scavenging of a range of macromolecules and
colloids that escape Kupffer phagocytosis. Punctate anti-AF488
staining of LSEC organelles indicated fCNT trafficking through the
early endosome, Golgi, and lysosome compartments and
supported receptor-mediated endocytosis as the mechanism of
clearance25,26. Furthermore, we now provide evidence that
Stabilin-1 and Stabilin-2 mediated endocytic clearance of fCNT
in vivo. The Stabilins are scavenger receptors that recognize and
clear a range of molecular substrates (for example, hyaluronan,
dermatan sulfate and acetylated low density lipoprotein)38.
Heparin clearance remains controversial notwithstanding strong
evidence for Stabilin-1 and Stabilin -2 binding27–31 countered by
reports that heparin is not a ligand for Stabilin-2 (refs 42,43).
Our new data definitely suggest that heparin did compete with
fCNT clearance by LSEC in vivo and with both Stabilin-1- and
Stabilin-2-expressing CHO cells in vitro. Heparin also reduced the
bidodistribution of fCNT in spleen and lymph tissue.
Stellate cells reside in the hepatic perisinusoidal space of Disse
intimately positioned between LSEC and hepatocytes41. The
paracrine secretion of vascular endothelial growth factor by
stellate cells and hepatocytes sustains the LSEC population and
promotes autocrine production of nitric oxide by LSEC30. It has
been shown that LSEC play an important role in maintenance of
stellate cell quiescence and prevent their activation and loss of the
vascular endothelial growth factor paracrine effect44. While
LSEC were the predominant target for fCNT, there was rare
evidence of fCNT in stellate cells (Supplementary Fig. 16).
Because one function of the LSEC is to guard these cells and
prevent activation30,44, occasionally fCNT may have been
taken-up by stellate cells. It is not clear how or if the stellate
cell recognized fCNT, but the literature on these perisinusoidal
cells is still developing.
The vascular endothelial architecture serves as the primary
conduit to distribute fCNT in vivo but there was no evidence
that these cells accumulated this nanomaterial (Fig. 2e). This
particular result calls attention to the differential functionality
and receptor expression of these two endothelial cell types with
continuous or discontinuous fenestrated cytoplasm. Cultured
endothelial cells were observed to accumulate SWCNT, albeit
under non-physiologic conditions over a prolonged time45,
however, our PET imaging and IF studies have not identified
any fCNT accumulation in the VE6,8,11.
Intact fCNT cleared the liver via secreted bile (Fig. 1f and
Supplementary Figs 2 and 3). The presence of intact radiolabeled
fCNT in the bile, intestines and faeces strongly supported a
mechanism of hepatobiliary clearance. The epithelial bile duct
cells that comprise these channels did not show any fCNT
accretion (Supplementary Fig. 8). We propose that a portion of
the fCNT in the sinusoid, not endocytosed by LSEC, diffused
from the Disse space into the biliary canaliculi and subsequently
mixed with bile. Because we observed no evidence of fCNT in
hepatocytes and the bile contained intact nanomaterial, it is
difficult to reconcile a mechanism whereby hepatocytes mediated
transport of fCNT from blood to bile. Evidence does exist for a
permeable barrier permitting pigments and cellular debris to
bypass hepatocyte processing and transit directly from blood to
bile46; scanning electron microscopy has shown 100 nm zones
between the space of Disse and the bile canaliculi that were
interpreted as sites for molecular diffusion47. These permeable
Disse/canalicular junctions have been utilized to effect retrograde,
non-viral gene therapy to the liver via infusion from the biliary
tree48. Conventional views of hepatocyte-mediated elimination of
blood-borne solutes into bile have overlooked this interesting
diffusion process across the Disse/canalicular junction49.
The spleen and lymph nodes also accumulated fCNT and
clearance was connected to the expression of both Stabilin
receptors in these tissues28–31. The implications are exciting
because one can now predict fCNT accumulation based on
receptor recognition. Lymph node clearance of fCNT has not been
reported until now and only discovered on the basis of lymph
expression of Stabilin receptors. Based on our identification of
Stabilin-mediated endocytosis of fCNT, we looked for and
confirmed accumulation in lymph nodes. The specific
accumulation of fCNT by these organs was observed in
biodistribution studies (Fig. 1f and Supplementary Fig. 2) and
blocked in heparin competition studies (Fig. 3a). In parallel with
the liver, the specialized splenic sinusoidal endothelium (SSEC)
also internalized fCNT while splenic macrophage clearance was
not observed (Supplementary Fig. 17). The splenic sinusoids are
tortuous VE termini lined with SSEC. The SSEC differ from LSEC
in that they exhibit continuous cytoplasm and disorganized
basement membrane30. The spleen is another important
reticuloendothelial tissue and it paralleled the liver in the cell
types that localized fCNT. Lymphatic endothelial cell accumulation
of fCNT now warrants further investigation.
These data contribute significantly to our understanding of the
hepatic processing of fCNT in vivo. The pharmacokinetic and
safety profile of fCNT in a non-human primate strongly proposes
extrapolation to humans. The predominant hepatic cell type that
accumulated this fibrillar nanocarbon was a professional
scavenger endothelial cell in the sinusoid that performed rapidly
and at high capacity. Mouse LSEC has 14±5 fenestrae per mm2
(humans have 15–25 per mm2) with diameters of 99±18 nm
(humans, 50odo300 nm)36. This is an avid, dedicated
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mammalian scavenger cell and in combination with intact biliary
elimination of fCNT has yielded a very favourable biological
outcome for soluble fibrillar nanocarbon in animal models.
Biocompatibility has been confirmed in several model systems
and now these results explain the action of the host on fCNT and
add further weight to arguments for use in man.
Potential therapeutic application of fCNT in humans could
focus on the critical role of LSE in numerous liver disorders
(for example, ischemia-reperfusion injury, sinusoidal obstructive
syndrome, nonalcoholic steatohepatitis, and pseudocapillarization
in the aging population)30. fCNT could be envisioned as a
molecular platform to specifically target the LSEC and
deliver therapeutic interventions (for example, small molecule
drugs or RNA interference) to treat LSEC-based disorders.
Hepato-targeted gene therapy strategies are being explored50,51
and fCNT could be included as a selective delivery platform
based on our favourable pharmacokinetic and toxicologic
data and the ability of fCNT to strongly bind, deliver and
unload siRNA in vivo52,53. Macrophages that express Stabilin-1
(not liver-resident Kupffer cells) should accumulate fCNT via
receptor-mediated processes and suggests further investigation54.
Also, now that lymph node clearance of fCNT has been described,
applications for lymph targeting strategies could be explored.
Methods
Synthesis and characterization of fCNTs. HiPCO SWCNT (Unidym) were
covalently functionalized with primary amines, Alexa Fluor 488 tetrafluorophenyl
ester (AF488-TFP, Invitrogen), AF680-SE (Invitrogen), and 2-(4-isothiocya-
natobenzyl)-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA,
Macrocyclics) and purified as described8. The amine loading per gram of SWCNT
was determined using the Sarin assay as described previously6. Characterization was
performed as described previously6,8,14 and confirmed the identity, stoichiometry
and purity of the nanomaterial. Radiolabeling with 86Y and 111In for imaging and
biodistribution was performed as previously described6,8,14.
Dynamic PET imaging to investigate pharmacokinetics. Dynamic imaging was
performed with the microPET Focus 120 (CTI Molecular Imaging) for the mouse
model (#, NCr/nu/nu, Taconic) as described8. Dynamic PET/CT imaging was
performed with a Siemens Biograph mCT PET/CT system for the non-human
primate model (#, Macaca fascicularis, Charles River) and described in the
Supplementary Information. For all in vivo experiments, housing and care were in
accordance with the Animal Welfare Act and the Guide for the Care and Use of
Laboratory Animals. The animal protocols were approved by the Institutional
Animal Care and Use Committee at MSKCC.
Biodistribution and elimination. Mice (#, NCr/nu/nu, Taconic) received an IV
injection of [111In]fCNT containing 0.04mg of SWCNT construct and 74 kBq
(0.002mCi) of 111In per mouse via the retroorbital sinus. The animals were placed
into 4 groups of 3–5 mice per group. Each group was sacrificed with CO2 aspiration at
1, 3, 24h and 7 days. Tissue samples (blood, heart, kidneys, muscle, bone, lung,
stomach, liver, spleen, lymph nodes (superficial cervical, axillary, brachial, renal
inguinal and lumbar), bile, small intestine (consisting of the duodenum, jejunum and
ileum), contents of the small intestine, large intestine (consisting of the caecum and
colon), contents of the large intestine), and faeces were collected, weighed and counted
using a g-counter (Packard Instrument, Co.) with a 315–435 keV energy window.
Standards of the injected formulation were counted to determine the %IDg 1.
Competition binding in vivo to identify the LSEC receptor. Mice (# and ~,
balb/c, Taconic) were placed into two groups of five mice. Each mouse in one
group received an intraperitoneal injection of 0.90ml of 20 g l 1 heparin (Sigma,
4180 USP units per mg) in normal sterile saline (NSS) at time 0 and then 30min
later those mice received a IV bolus of 0.10ml of 20 g l 1 heparin followed
immediately by 0.01mg of [86Y]fCNT in 0.10ml via retroorbital sinus IV injection.
The mice in the control group (n¼ 5) received only a 0.01mg dose of [86Y]fCNT in
0.10ml via retroorbital sinus IV injection. At 1 h post injection of the radiolabeled
fCNT, the mice were euthanized and the blood, liver, spleen and lymph nodes were
harvested, weighed, and counted using a g-counter.
Immunofluorescence microscopy. Mice (#, NCr/nu/nu) received 0.01mg of
fCNT in 0.10ml via retroorbital sinus IV injection. Mice were euthanized at 1, 3, 5,
20, 40, 60, 180min, 1, 3, 7 or 30 days and the liver, kidneys and spleen collected for
IF analyses. Controls included naive tissue (no construct was injected) to determine
baseline autofluorescence, hydrolyzed-AF488 dye that was not conjugated to
SWCNT (at 1 and 60min post injection), and isotype-control staining IgG (non-
specific IgG as primary antibody). The immunofluorescent staining was performed
in the Molecular Cytology Core Facility of Memorial Sloan-Kettering Cancer
Center using Discovery XT processor (Ventana Medical Systems). Double and
triple staining experiments were performed sequentially55. Specific details of the IF
staining, microscopy and imaging are described in the Supplementary Information.
Isolate LSEC and Kupffer cells from mouse liver. LSECs and Kupffer cells were
extracted from mouse liver by collagenase perfusion (Liberase TM, Roche), via the
portal vein56. LSEC were purified using anti-CD146 immunomagnetic beads
(Miltenyi Biotec, Bergisch-Gladbach, Germany) and Kupffer cells similarly isolated
using an anti-F4/80 biotin and streptavidin immunomagnetic beads (Miltenyi
Biotec)57. The identity and purity of the two populations was analysed by flow
cytometry, using Fluorescein isothiocyanate-labelled check reagents (Miltenyi
Biotec), and by PCR analyses. Expression of the Kupffer cell marker Emr1 and
LSEC marker Lyve1, along with Stab1 and Stab2 was performed by RT-qPCR.
Liver was examined for apoptosis and immune cell infiltration after fCNT.
Murine liver sections (~, balb/c, Taconic) were incubated in primary antibody
solutions (rabbit anti-Alexa488 antibody (Molecular Probes) at 0.5 mgml 1; rabbit
anti-CD3 antibody (DAKO) at 1.2 mgml 1; rabbit anti-Cleaved Caspase-3 anti-
body (Cell Signalling) at 0.1 mgml 1; or TdT-biotin-dUTP (Roche) for TUNEL
staining. Representative snapshots were taken from the scanned images and ana-
lysed for signal intensity or counts, normalized to tissue area, using image analysis
software Metamorph (Molecular Devices, PA). Statistics (Student’s t-tests) were
performed and graphs were made using Prism6 (GraphPad, LaJolla, CA).
Human hepatocyte microsphere toxicity study. Human liver microsphere tissue
(Insphero, Glattbrugg, CH) was exposed to fCNT. Liver tissue spheres were
exposed for 1, 2 or 3 days to 15 and 30mg l 1 concentrations of fCNT in vitro.
Hepatocyte microsphere tissue sections were stained with H&E, TUNEL (Promega,
DeadEnd Colorimetric TUNEL System cat. no. G7130), and cleaved caspase-3 (Cell
Signalling Technology, Cleaved Caspase-3 (Asp175) Antibody, cat. no. 9661).
In vitro endocytosis assays. CHO cells were stably transfected with empty vector,
full-length human Stabilin-1 and Stabilin-2 expression constructs were generated
as described31,58,59. For endocytosis, fCNT labelled with AF488 were added in
concentration 15mg l 1 in serum free F12 medium for 30min, 37 C. AcLDL-
AF488 (Life Technologies) in concentration 5mg l 1 was used as a positive control
for endocytic activity. Quantification of bound/internalized fluorescent ligands was
performed with FACSCanto II flow cytometer (BD Biosciences) according to
standard protocols. Data were visualized and analysed using FlowJo 7.6.5 software.
For detection of fCNT endocytosis by confocal microscopy CHO cells were
cultured on coverslips, fixed in PFA and stained using guinea pig anti-Stabilin-1
(clone GP2, self-produced) or mouse anti-Stabilin-2 (clone 3.1) abs as described31.
fCNT were visualized using rabbit anti-AF488 antibody. Secondary antibodies were
donkey anti-guinea pig or donkey anti-mouse labelled with Cy3, and donkey
anti-rabbit-AF488 (all from Dianova). Confocal microscopy analysis was
performed using Leica TCS SP8 microscope. Data were acquired and analysed with
Leica Confocal software. CHO cells were pre-incubated with heparin (1mgml 1)
in serum free F12 medium for 30min 37 C followed by addition of fCNT for
another 30min without changing medium. Endocytosed fCNT were detected by
flow cytometry as described above.
Data analyses. Three-dimensional region-of-interest analysis on PET images
was performed with AsiPRO VM 5.0 software (Concorde Microsystems).
Widefield and confocal microsopy images were evaluated using ImageJ (NIH,
http://rsb.info.nih.gov/ij/), AxioVision LE (Zeiss), and Amira 4.1 (Visage Imaging,
Inc.) software. Graphs were constructed and statistical data were evaluated using
Graphpad Prism 3.0 (Graphpad Software, Inc.). Statistical comparison between two
experimental groups was performed using a t-test (unpaired comparison).
Data availability. The data that support the findings of this study are available
from the corresponding author upon request.
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